EQUITY RESEARCH Modern Dental Group (3600 HK)

Modern Dental

New PT Implies 100% Upside; Significant Margin Expansion Ahead

25 April 2021

Key Takeaway

We are upgrading Modern Dental to a Buy with a revised PT of HK\$7.30, implying 100% upside. Our upgrade is based on: 1) its defensiveness, and more importantly, its ability to go against the tide amid COVID-19, and 2) significant margin expansion (we expect net margin to expand from current 4.9% to 15-20%). Modern Dental is currently trading at 6.2x/5.4x our 2021E/2022E EV/EBITDA (vs. its dental peers with consensus average of 17.3/15.5x).

Sales growth to rise beyond pre-COVID levels – Modern Dental surprised us with its rapid sales recovery from COVID-19, especially in 4Q20. (1Q20 sales growth: -9% YOY, 2Q20: -40% YOY, 3Q20: +6% YOY, 4Q20: +8% YOY). The recovery largely comes from: 1) inelastic demand for dental products, and 2) market share gain from industry consolidation as weaker/smaller competitors exited the industry. Note that denture devices industry is highly fragmented but characterized by sticky customers. Hence, we see Modern Dental benefiting from market consolidation during COVID-19 as a windfall, with the company gaining sticky clients and sustainable revenues. With the low sales base in 1H20 (-25% YOY), we deem 1H21 to be strong. We expect 2021E sales growth to be higher than pre-COVID levels (+16% YOY). In our view, future sales growth will come from: 1) higher penetration of its digitalized products (intraoral scanning, 3D-printing, etc.), new products (such as its aligner), and 2) further geographical expansion to countries such as Singapore and Vietnam. In 2022E-23E, we expect sales to grow by a CAGR of +7.5% (vs. industry average of 5% to 6%) thanks to abovementioned drivers.

Margin expansion – We believe Modern Dental's low net margin era (4% to 7%), seen in 2015 to 2020, is over. In fact, net margin was always close to 10% excluding the MicroDental US acquisition in 2016 (and COVID-19 in 2020). We expect net margin to move from current mid-single digit, to low-teens in 2021E, to mid-high teens in 2022E onwards (2020: 4.9%, 2021E: 12.9%, 2022E: 15%, 2025E+: 18%). This is likely to be driven by: 1) MicroDental turning profitable in 2019, and being further streamlined during COVID-19, with higher gross margins (around 45%) than in the past (around 30%), 2) its new Dongguan capacity reaching favorable utilization rate, and generating economies of scale for Modern Dental, 3) digitalization, which aids market share gain, while offering a favorable cost profile (lower freight cost, fewer remakes and improved working capital through faster AR turnover).

Current valuation is highly attractive – Our valuation of HK\$7.30 is based on 1.0x PEG ratio, using our <u>2022E-23E</u> EPS CAGR of 21%. This is compared to our DCF-based valuation of HK\$9.20 per share, which shows more upside. **Dividends**: Note that Modern Dental has been increasing its dividend payout since 2018 (2018: HK 0.033, 2019: HK0.053, 2020: HK0.070) despite COVID-19. We expect the company to register dividend payout ratios of 35-40% going forward on rising EPS. Our DDM analysis shows that based on dividends alone, Modern Dental could be worth at least HK3.0 per share (2021E: HK0.12, r = 7.0%, g = 3.0%).

Risks – ASP pressure, competition, and M&A integration risks.

Rating | Target | Estimate Change

ASIA-PACIFIC excl. Japan | Healthcare Services

RATING	BUY (FROM HOLD)
PRICE	HK\$3.59^
MARKET CAP	HK\$3.5B / \$445.2M
PRICE TARGET (PT)	HK\$7.30 (FROM HK\$1.30)
UPSIDE SCENARIO PT	HK\$9.20
DOWNSIDE SCENARIO	PT HK\$3.00

*Prior trading day's closing price unless otherwise noted.

FY Dec				
HKD	2020A	2021E	2022E	2023E
EPS	↓ 0.11	1 0.34	1 0.42	0.50
Prev.	0.12	0.19	0 22	

Christopher Lui * Equity Analyst +852 3743 8768 christopher.lui@jefferies.com

> Ruyi Tang, CFA * Equity Analyst +852 3743 8074 ruyi.tang@jefferies.com

Gabriel Wong, PhD * Equity Associate +852 3743 8017 gwong2@jefferies.com

Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 10 to 15 of this report.

MODERN DENTAL (3600 HK)

		Estimates		
нк\$	2020A	2021E	2022E	2023E
Rev. (MM)	✤ 2,190.2	4 2,536.4	4 2,751.8	2,932.9
Previous	2,212.5	2,591.0	2,783.5	
Net Profit	✤ 107.8	1 327.6	1 401.4	476.1
Previous	115.9	180.4	207.7	
EPS	✤ 0.11	1.34	1 0.42	0.50
Previous	0.12	0.19	0.22	

Market Data	
52-Week Range:	HK\$3.59 - HK\$1.15
Total Entprs. Value	HK\$3.6B
Avg. Daily Value MM (USD)	1.58
Float (%)	34.0%

The Long View

Scenarios

Base Case

Margin expansion and slightly-faster than industry growth;

PT of HK\$7.3 derived from PEG-based valuation.

Upside Scenario

Less ASP pressure;

New product launches and fast sales ramp-up;

New M&As with attractive valuation;

PT of HK\$9.2 derived from DCF-based valuation.

Downside Scenario

Higher ASP downside pressure;

COVID-19 situation worsens, causing more lockdowns;

PT of HK\$3.0 derived from DDM valuation.

Investment Thesis / Where We Differ

Modern Dental is a global leading dental prosthetic device provider. We like its global layout and scale, efficient distribution network, cost advantages and consolidation opportunities. We expect Modern Dental to grow at a faster rate than the industry, thanks to higher penetration of its existing and new products, margin expansion from economies of scale and costsaving strategies.

Catalysts

New product launches/rising penetration; New M&A deals.

Exhibit 1 - Our valuation of HK\$7.30 is based on 1.0x PEG ratio using our 2022E-23E EPS CAGR of 21%

	2019	2020E	2021E	2022E	2023E
Revenue (HK\$ '000)	2,399,548	2,190,208	2,536,419	2,751,836	2,932,886
Net profit (HK\$ '000)	161,557	107,763	327,568	401,373	476,074
Net margin	6.7%	4.9%	12.9%	14.6%	16.2%
Shares outstanding ('000)	980,162	961,914	962,227	962,227	962,227
EPS (HK\$)	0.16	0.11	0.34	0.42	0.49
EPS YOY%		-32%	204%	23%	19%
EPS CAGR				2	1%
PEG			1.0x		
P/E			21x		
Valuation (HK\$)			7.0		
Net cash and others (HK\$)			0.3		
Total PT (HK\$)			7.3		

Source: Jefferies

Exhibit 2 - Sales recovery by quarter in 2020

Markets	Revenue YOY% growth									
	1Q20	2Q20	3Q20	4Q20						
Europe	-4%	-36%	9%	13%						
Greater China	-37%	-10%	5%	7%						
North America	1%	-65%	-1%	-4%						
Australia	-2%	-46%	12%	21%						
Others	9%	-41%	43%	24%						
Total	-9%	-40%	6%	8%						

Source: Company data

Exhibit 3 - Peer valuation comparison

		Share price	Mkt cap	E	BITDA Y	OY grow	th		EBITDA	margin			EV/E	BTIDA			P	/E			PE	G	
Company	Ticker	(local ccy)	initi oup		(%	6)			(%	6)			()	()			()	()			()	()	
		21/4/2021	(US\$ mn)	2020	2021E	2022E	2023E	2020	2021E	2022E	2023E	2020	2021E	2022E	2023E	2020	2021E	2022E	2023E	2020	2021E	2022E	2023E
PRC-listed																							
Topchoice	600763 CH	291.00	14,374	3.8	51.3	27.5	30.7	34.4	38.0	38.2	38.6	114.7	85.8	67.3	51.5	189.0	126.6	96.8	74.6	4.8	4.1	3.2	2.5
Average			14,374	3.8	51.3	27.5	30.7	34.4	38.0	38.2	38.6	114.7	85.8	67.3	51.5	189.0	126.6	96.8	74.6	4.8	4.1	3.2	2.5
Overseas-listed																							
Straumann	STMN SE	1225.00	21,249	(46.7)	100.4	17.4	14.6	18.0	30.8	31.6	32.3	48.3	38.2	32.5	28.4	213.0	57.8	48.1	40.9	1.9	3.3	3.2	2.7
Henry Schein	HSIC US	72.30	10,286	(18.5)	14.8	4.3	4.7	8.0	8.0	8.2	8.3	15.0	12.4	11.9	11.4	25.5	19.4	17.9	16.1	1.4	2.7	2.2	2.0
Envista	NVST US	43.60	7,004	(54.5)	131.9	10.3	5.4	8.9	17.2	18.1	18.4	29.0	16.8	15.2	14.5	207.6	25.8	23.2	20.7	1.0	2.2	2.2	1.9
Osstem	048260 KQ	89800.00	1,140	93.6	3.0	12.9	2.7	19.8	17.2	17.2	16.4	14.5	10.8	9.6	9.3	11.4	18.3	15.6	10.0	NA	0.6	0.3	0.2
Q&M Dental	QNM SP	0.62	364	(0.2)	41.0	14.1	8.0	27.5	25.6	25.2	25.3	19.9	10.7	9.4	8.7	24.6	17.6	13.4	12.8	0.7	1.0	1.5	1.4
Pacific Smile	PSQ AU	2.79	345	47.3	5.4	3.2	19.4	27.4	21.6	19.6	20.5	23.0	14.9	14.5	12.1	66.4	28.5	29.7	24.9	1.3	3.4	1.5	1.3
Average			6,731	3.5	49.4	10.4	9.1	18.3	20.1	20.0	20.2	24.9	17.3	15.5	14.1	91.4	27.9	24.6	20.9	1.2	2.2	1.8	1.6

Source: Bloomberg

Exhibit 4 - FY20 results review

P&L FY20 (vs. FY19) and 2H20 (vs. 1H20)	EV20	EV40	YOY%	21120	41120	
(HK\$ '000)	FY20	FY19	YOY%	2H20	1H20	HOH%
Net sales	2,190,208	2,399,548	-9%	1,292,985	897,223	44%
COGS	(1,100,220)	(1,246,617)	-12%	(617,020)	(483,200)	28%
Gross profit	1,089,988	1,152,931	-5%	675,965	414,023	63%
Selling expenses	(251,410)	(294,352)	-15%	(151,942)	(99,468)	53%
G&A expenses	(549,383)	(608,278)	-10%	(276,597)	(272,786)	1%
R&D expenses	(6,434)	(7,447)	-14%	(3,247)	(3,187)	2%
Operating income	282,761	242,854	16%	244,179	38,582	533%
D&A	135,751	152,904	-11%	66,270	69,481	-5%
EBITDA	418,512	395,758	6%	310,449	108,063	187%
Other income	26,139	13,467	94%	21,167	4,972	326%
Other gains / (loss) net	(150,695)	(17,177)	777%	4,536	(155,231)	
Finance income	1,255	1,270	-1%	420	835	-50%
Finance costs	(33,699)	(37,902)	-11%	(13,885)	(19,814)	-30%
Share of results of associates	(1,537)	(504)	205%	(1,092)	(445)	145%
Pretax income	124,224	202,008	-39%	255,325	(131,101)	
Taxes	(16,565)	(41,563)	-60%	(8,164)	(8,401)	-3%
Effective tax rate	13%	21%	-35%	3%	-6%	
Net income	107,659	160,445	-33%	247,161	(139,502)	
Minority Interest	104	1,112	-91%	(44)	148	
Net income to common	107,763	161,557	-33%	247,117	(139,354)	
Diluted EPS (HK\$)	0.112	0.165	-32%	0.257	(0.145)	
Adjusted net profit to common	224,274	164,810	36%	209,608	14,666	1329%
Adjusted diluted EPS (HK\$)	0.233	0.168	39%	0.218	0.015	1330%
Diluted sh o/s (000)	961,914	980,162	-2%	961,397	962,432	0%
Margin Analysis	FY20	FY19	Delta	2H20	1H20	Delta
Gross margin	49.8%	48.0%	1.7%	52.3%	46.1%	6.1%
Selling expense as % of sales	11.5%	12.3%	-0.8%	11.8%	11.1%	0.7%
G&A expense as % of sales	25.1%	25.3%	-0.3%	21.4%	30.4%	-9.0%
R&D expense as % of sales	0.3%	0.3%	0.0%	0.3%	0.4%	-0.1%
Operating margin	12.9%	10.1%	2.8%	18.9%	4.3%	14.6%
EBITDA margin	19.1%	16.5%	2.6%	24.0%	12.0%	12.0%
Pretax margin	5.7%	8.4%	-2.7%	19.7%	-14.6%	34.4%
Net margin	4.9%	6.7%	-1.8%	19.1%	-15.5%	34.6%
Adjusted net margin	10.2%	6.9%	3.4%	16.2%	1.6%	14.6%
	1012 / 0	0.0 / 0	0.470	10.270	11070	14.070
Revenue breakdown FY20 (vs. FY19) and 2H20 ((vs. 1H20)					
(HK\$ '000)	FY20	FY19	YOY%	2H20	1H20	HOH%
Revenue	2,190,208	2,399,548	-9%	1,292,985	897,223	44%
Fixed prosthetic devices	1,516,083	1,682,419	-10%	889,908	626,175	42%
Removable prosthetic devices	403,330	460,099	-12%	240,728	162,602	48%
	180,812		-11%	109,699	71,113	54%
()ther devices		203 730			71,110	
Other devices		203,730			37 333	/1%
Others	89,983	203,730 53,300	69%	52,650	37,333	41%
Others		,			37,333	41%
Others Key balance sheet and operating metrics	89,983	53,300	69%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000)	89,983 FY20	53,300 FY19	69%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000) Cash and cash equivalent	89,983 FY20 702,655	53,300 FY19 399,235	69% YOY% 76%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000) Cash and cash equivalent ST Bank borrowings	89,983 FY20 702,655 187,680	53,300 FY19 399,235 106,336	69% YOY% 76% 76%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000) Cash and cash equivalent ST Bank borrowings LT Bank Borrowings	89,983 FY20 702,655 187,680 673,063	53,300 FY19 399,235 106,336 696,012	69% YOY% 76%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000) Cash and cash equivalent ST Bank borrowings LT Bank Borrowings Net cash	89,983 FY20 702,655 187,680 673,063 (158,088)	53,300 FY19 399,235 106,336 696,012 (403,113)	69% YOY% 76% -3%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000) Cash and cash equivalent ST Bank borrowings LT Bank Borrowings Net cash Net cash from operating activities	89,983 FY20 702,655 187,680 673,063 (158,088) 400,177	53,300 FY19 399,235 106,336 696,012 (403,113) 342,226	69% YOY% 76% 76% -3% 17%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000) Cash and cash equivalent ST Bank borrowings LT Bank Borrowings Net cash Net cash from operating activities Capex	89,983 FY20 702,655 187,680 673,063 (158,088) 400,177 72,446	53,300 FY19 399,235 106,336 696,012 (403,113) 342,226 150,738	69% YOY% 76% -3% 17% -52%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000) Cash and cash equivalent ST Bank borrowings LT Bank Borrowings Net cash Net cash from operating activities Capex FCF	89,983 FY20 702,655 187,680 673,063 (158,088) 400,177 72,446 327,731	53,300 FY19 399,235 106,336 696,012 (403,113) 342,226 150,738 191,488	69% YOY% 76% 76% -3% 17% -52% 71%		37,333	41%
Others Key balance sheet and operating metrics (HK\$ '000) Cash and cash equivalent ST Bank borrowings LT Bank Borrowings Net cash Net cash from operating activities Capex	89,983 FY20 702,655 187,680 673,063 (158,088) 400,177 72,446	53,300 FY19 399,235 106,336 696,012 (403,113) 342,226 150,738	69% YOY% 76% -3% 17% -52%		37,333	41%

Source: Company data

Exhibit 5 - Revenue model

HK\$ '000	2017	2018	2019	2020	2021E	2022E	2023E	2024E	2025E
Revenue	2,181,292	2,315,467	2,399,548	2,190,208	2,536,419	2,751,836	2,932,886	3,081,217	3,206,925
Fixed prosthetic devices	1,575,585	1,664,457	1,682,419	1,516,083	1,778,541	1,941,099	2,078,917	2,184,110	2,272,348
Removable prosthetic devices	417,000	451,304	460,099	403,330	460,658	493,365	518,329	544,556	566,556
Other devices	172,467	179,128	203,730	180,812	193,741	203,544	213,843	224,664	233,740
Others	16,240	20,578	53,300	89,983	103,480	113,828	121,796	127,886	134,281
YOY%									
Revenue	33%	6%	4%	-9%	16%	8%	7%	5%	4%
Fixed prosthetic devices	39%	6%	1%	-10%	17%	9%	7%	5%	4%
Removable prosthetic devices	17%	8%	2%	-12%	14%	7%	5%	5%	4%
Other devices	26%	4%	14%	-11%	7%	5%	5%	5%	4%
Others	1%	27%	159%	69%	15%	10%	7%	5%	5%
Sales volume									
Total sales volume	1,738,966	1,752,491	1,807,754	1,596,322	1,792,981	1,897,111	1,976,791	2,036,095	2,076,817
Fixed prosthetic devices	1,069,391	1,033,151	1,029,746	925,096	1,063,860	1,138,331	1,195,247	1,231,105	1,255,727
Removable prosthetic devices	387,501	401,232	426,365	347,618	389,332	408,799	421,063	433,695	442,369
Other devices	282,074	318,108	351,643	323,608	339,788	349,982	360,482	371,296	378,722
YOY%									
Sales volume	25%	1%	3%	-12%	12%	6%	4%	3%	2%
Fixed prosthetic devices	33%	-3%	0%	-10%	15%	7%	5%	3%	2%
Removable prosthetic devices	9%	4%	6%	-18%	12%	5%	3%	3%	2%
Other devices	21%	13%	11%	-8%	5%	3%	3%	3%	2%
ASP (RMB)									
Overall ASP	1,254	1,321	1,327	1,372	1,415	1,451	1,484	1,513	1,544
Fixed prosthetic devices	1,473	1,611	1,634	1,639	1,672	1,705	1,739	1,774	1,810
Removable prosthetic devices	1,076	1,125	1,079	1,160	1,183	1,207	1,231	1,256	1,281
Other devices	611	563	579	559	570	582	593	605	617
YOY%									
ASP	6%	5%	0%	3%	3%	3%	2%	2%	2%
Fixed prosthetic devices	4%	9%	1%	0%	2%	2%	2%	2%	2%
Removable prosthetic devices	8%	5%	-4%	8%	2%	2%	2%	2%	2%
Other devices	5%	-8%	3%	-3%	2%	2%	2%	2%	2%
Gross margin									
Overall gross margin	48.7%	46.6%	48.0%	49.8%	51.6%	52.6%	53.4%	54.3%	55.2%
Fixed prosthetic devices	48.7%	46.9%	49.2%	51.2%	53.0%	54.0%	55.0%	56.0%	57.0%
Removable prosthetic devices	48.1%	46.6%	47.3%	50.1%	52.0%	53.0%	54.0%	55.0%	56.0%
Others	49.8%	44.2%	42.0%	41.3%	43.0%	43.0%	43.0%	43.0%	43.0%

Exhibit 6 - Income statement

Income Statement		- 0040	- 00.40		00045	00005	00005	000.45	-00055
HK\$ '000	2017	2018	2019	2020	2021E	2022E	2023E	2024E	2025E
Net sales	2,181,292	2,315,467	2,399,548	2,190,208	2,536,419	2,751,836	2,932,886	3,081,217	3,206,925
COGS	(1,119,780)	(1,236,131)	(1,246,617)	(1,100,220)	(1,226,446)	(1,305,689)	(1,365,259)	(1,407,012)	(1,436,166)
Gross profit	1,061,512	1,079,336	1,152,931	1,089,988	1,309,974	1,446,147	1,567,627	1,674,204	1,770,759
Selling expenses	(265,926)	(275,142)	(294,352)	(251,410)	(304,370)	(316,461)	(322,617)	(338,934)	(352,762)
G&A expenses	(586,525)	(616,797)	(608,278)	(549,383)	(558,012)	(591,645)	(615,906)	(647,055)	(673,454)
R&D expenses	0	(13,761)	(7,447)	(6,434)	(7,451)	(8,084)	(8,616)	(9,051)	(9,421)
Operating income	209,061	173,636	242,854	282,761	440,140	529,957	620,488	679,163	735,122
D&A	90,259	95,478	152,904	135,751	139,380	140,565	142,381	137,559	133,433
EBITDA	299,320	269,114	395,758	418,512	579,520	670,522	762,869	816,722	868,555
Other income	23,469	10,797	13,467	26,139	0	0	0	0	0
Other gains / (loss) net	(1,582)	(12,533)	(17,177)	(150,695)	0	0	0	0	0
Finance income	443	547	1,270	1,255	2,204	2,595	3,394	4,100	5,027
Finance costs	(28,582)	(51,516)	(37,902)	(33,699)	(31,741)	(29,784)	(27,826)	(25,869)	(23,911)
Share of results of associates	(1,288)	(1,929)	(504)	(1,537)	(1,537)	(1,537)	(1,537)	(1,537)	(1,537)
Pretax income	201,521	119,002	202,008	124,224	409,065	501,232	594,518	655,857	714,701
Taxes	(44,158)	(35,762)	(41,563)	(16,565)	(81,813)	(100,246)	(118,904)	(131,171)	(142,940)
Effective tax rate	21.9%	30.1%	20.6%	13.3%	20.0%	20.0%	20.0%	20.0%	20.0%
Net income	157,363	83,240	160,445	107,659	327,252	400,985	475,615	524,686	571,760
Minority Interest	(1,992)	2,151	1,112	104	316	387	459	507	552
Net income to common	155,371	85,391	161,557	107,763	327,568	401,373	476,074	525,193	572,313
Diluted EPS (HK\$)	0.156	0.086	0.165	0.112	0.340	0.417	0.495	0.546	0.595
Adjusted net profit to common	155,371	96,951	164,810	224,274	327,568	401,373	476,074	525,193	572,313
Adjusted diluted EPS (HK\$)	0.156	0.097	0.168	0.233	0.340	0.417	0.495	0.546	0.595
Diluted sh o/s (000)	998,520	997,151	980,162	961,914	962,227	962,227	962,227	962,227	962,227
Dividend	2017	2018	2019	2020	2021E	2022E	2023E	2024E	2025E
DPS (HK\$)	0.05	0.03	0.05	0.07	0.12	0.15	0.17	0.19	0.21
YOY%	52%	-28%	61%	32%	70%	23%	19%	10%	9%
Dividend payout ratio	30%	34%	32%	30%	35%	35%	35%	35%	35%
Margin Analysis	2017	2018	2019	2020	2021E	2022E	2023E	2024E	2025E
Gross margin	48.7%	46.6%	48.0%	49.8%	51.6%	52.6%	53.4%	54.3%	55.2%
Selling expense as % of sales	12.2%	11.9%	12.3%	11.5%	12.0%	11.5%	11.0%	11.0%	11.0%
G&A expense as % of sales	26.9%	26.6%	25.3%	25.1%	22.0%	21.5%	21.0%	21.0%	21.0%
R&D expense as % of sales	0.0%	0.6%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Operating margin	9.6%	7.5%	10.1%	12.9%	17.4%	19.3%	21.2%	22.0%	22.9%
EBITDA margin	13.7%	11.6%	16.5%	19.1%	22.8%	24.4%	26.0%	26.5%	27.1%
Pretax margin	9.2%	5.1%	8.4%	5.7%	16.1%	18.2%	20.3%	21.3%	22.3%
Net margin	7.1%	3.7%	6.7%	4.9%	12.9%	14.6%	16.2%	17.0%	17.8%
Adjusted net margin	7.1%	4.2%	6.9%	10.2%	12.9%	14.6%	16.2%	17.0%	17.8%
	0047	0040	0040	0000	00045	00005	00005	000.45	00055
% YOY Change	2017	2018	2019	2020	2021E	2022E	2023E	2024E	2025E
Net sales	33%	6%	4%	-9%	16%	8%	7%	5%	4%
Gross profit	21%	2%	7%	-5%	20%	10%	8%	7%	6%
Selling expense	44%	3%	7%	-15%	21%	4%	2%	5%	4%
G&A expense	17%	5%	-1%	-10%	2%	6%	4%	5%	4%
R&D expense	NA	NA	-46%	-14%	16%	8%	7%	5%	4%
Operating income	7%	-17%	40%	16%	56%	20%	17%	9%	8%
EBITDA	12%	-10%	47%	6%	38%	16%	14%	7%	6%
Pretax income	32%	-41%	70%	-39%	229%	23%	19%	10%	9%
Net income	53%	-45%	89%	-33%	204%	23%	19%	10%	9%
Adjusted net income	53%	-38%	70%	36%	46%	23%	19%	10%	9%
Adjusted diluted EPS	52%	-38%	73%	39%	46%	23%	19%	10%	9%
Diluted shares outstanding	1%	0%	-2%	-2%	0%	0%	0%	0%	0%



Exhibit 7 - Balance sheet

Balance sheet									
НК\$ '000	2017	2018	2019	2020	2021E	2022E	2023E	2024E	2025E
Inventories	81,861	110,906	115,274	128,021	107,188	143,218	118,612	151,226	124,203
Trade receivables	413,682	380,443	423,271	473,105	430,277	474,436	489,800	523,202	531,129
Cash and cash equivalent	368,660	380,393	393,905	697,827	962,616	1,134,580	1,484,979	1,794,970	2,201,877
Pledged bank deposits	12,467	11,482	5,330	4,828	4,828	4,828	4,828	4,828	4,828
Prepayments and other receivables	59,858	58,294	64,739	71,783	71,783	71,783	71,783	71,783	71,783
Other current asset	10,983	17,851	20,098	15,173	15,173	15,173	15,173	15,173	15,173
Current assets	947,511	959,369	1,022,617	1,390,737	1,591,865	1,844,018	2,185,176	2,561,183	2,948,994
PP&E	326,703	433,810	498,613	518,915	558,102	601,203	587,717	578,815	573,496
Intangible assets	1,785,948	1,671,901	1,800,724	1,690,625	1,613,515	1,539,922	1,469,686	1,402,653	1,338,677
Investment in associates	10,325	8,396	9,625	761	761	761	761	761	761
Deferred income tax	9,090	10,814	11,832	49,294	49,294	49,294	49,294	49,294	49,294
Other non-current assets	60,653	21,771	17,830	14,756	13,219	11,682	10,145	8,608	7,071
Non-Current assets	2,192,719	2,146,692	2,338,624	2,274,351	2,234,891	2,202,862	2,117,602	2,040,131	1,969,299
Total Assets	3,140,230	3,106,061	3,361,241	3,665,088	3,826,756	4,046,880	4,302,778	4,601,313	4,918,292
Trade payables	57,195	64,319	70,026	67,670	66,735	76,354	73,263	80,930	76,458
Accruals and other payables	179,947	170,440	197,839	230,627	230,627	230,627	230,627	230,627	230,627
Current income tax liabilities	43,477	40,152	48,902	73,881	73,881	73,881	73,881	73,881	73,881
ST Bank borrowings	270,360	30,171	106,336	187,680	187,680	187,680	187,680	187,680	187,680
Other current liabilities	0	0	53,337	41,395	41,395	41,395	41,395	41,395	41,395
Current Liabilities	550,979	305,082	476,440	601,253	600,318	609,937	606,846	614,513	610,041
LT Bank Borrowings	447,098	779,072	696,012	673,063	623,063	573,063	523,063	473,063	423,063
Deferred tax liabilities	23,379	18,774	16,047	11,250	11,250	11,250	11,250	11,250	11,250
Other non-current liabilities	13,781	10,931	150,335	123,005	123,005	123,005	123,005	123,005	123,005
Non-Current Liabilities	484,258	808,777	862,394	807,318	757,318	707,318	657,318	607,318	557,318
Total Liabilities	1,035,237	1,113,859	1,338,834	1,408,571	1,357,636	1,317,255	1,264,164	1,221,831	1,167,359
Share capital	77,500	77,500	76,078	74,592	74,592	74,592	74,592	74,592	74,592
Reserve	2,019,990	1,918,744	1,944,742	2,173,069	2,385,988	2,646,881	2,956,329	3,297,704	3,669,707
Shareholders' Equity (w/out MI)	2,097,490	1,996,244	2,020,820	2,247,661	2,460,580	2,721,473	3,030,921	3,372,296	3,744,299
Minority interest	7,503	(4,042)	1,587	8,856	8,540	8,153	7,693	7,186	6,634
Total Liabilities and SE	3,140,230	3,106,061	3,361,241	3,665,088	3,826,756	4,046,880	4,302,778	4,601,313	4,918,292



Exhibit 8 - Cash flow statement

Cash Flow Statement									
HK\$ '000	2017	2018	2019	2020	2021E	2022E	2023E	2024E	2025E
Profit before tax	201,521	119,002	202,008	124,224	409,065	501,232	594,518	655,857	714,701
Depreciation of PP&E	53,183	57,439	57,551	58,641	62,270	66,972	72,144	70,526	69,458
Amortization of intangible assets	37,076	38,039	95,353	77,110	77,110	73,593	70,236	67,033	63,975
Asset impairment	(2,715)	516	195	0	0	0	0	0	0
Share of results of associates	1,288	1,929	504	1,537	1,537	1,537	1,537	1,537	1,537
Interest income	(443)	(547)	(1,270)	(1,255)	(2,204)	(2,595)	(3,394)	(4,100)	(5,027)
Finance cost	28,582	51,516	37,902	33,699	31,741	29,784	27,826	25,869	23,911
Gain/loss on disposal of PP&E	(95)	156	(487)	0	0	0	0	0	0
Others	6,748	(226)	1,270	216,844	0	0	0	0	0
Net change in WC	(73,983)	(9,970)	(11,818)	(89,261)	62,726	(70,570)	6,151	(58,349)	14,624
Cash generated from operations	251,162	257,854	381,208	421,539	642,246	599,952	769,020	758,373	883,179
Income tax paid	(56,489)	(52,961)	(38,982)	(21,362)	(81,813)	(100,246)	(118,904)	(131,171)	(142,940)
Net cash from operating activities	194,673	204,893	342,226	400,177	560,433	499,706	650,116	627,202	740,239
Proceeds from disposal of PP&E	1,506	1,696	7,762	0	0	0	0	0	0
Finance income	443	547	1,270	1,255	2,204	2,595	3,394	4,100	5,027
Acquisition of PP&E	(191,360)	(140,679)	(138,712)	(72,446)	(101,457)	(110,073)	(58,658)	(61,624)	(64,139)
Acquisition of intangible assets	0	0	(8,802)	0	0	0	0	0	(11,111)
Acquisition of subsidiaries	1,563	0	(3,224)	0	0	0	0	0	0
Increase in restricted cash	(8,741)	985	6,152	0	0	0	0	0	0
Others	(15,178)	(5,151)	(3,032)	24,227	0	0	0	0	0
Net cash from investing activities	(211,767)	(142,602)	(138,586)	(46,964)	(99,253)	(107,478)	(55,264)	(57,525)	(59,112)
	(=,,	(,	(100,000)	(,	(,)	(,	(,,	(,)	(,,
Proceeds from bank borrowings	206,895	805,006	20,000	81,344	0	0	0	0	0
Repayments of bank borrowings	(118,602)	(742,513)	(29,970)	(22,949)	(50,000)	(50,000)	(50,000)	(50,000)	(50,000)
Proceeds from shares issued	0	0	0	0	0	0	0	0	0
Shares repurchase	0	(16,420)	(30,819)	(6,867)	0	0	0	0	0
Dividends paid to equity holders	(34,000)	(40,000)	(44,085)	(67,373)	(114,649)	(140,480)	(166,626)	(183,817)	(200,309)
Acquisitions of non-controlling interests	0	(20,591)	(5,585)	0	0	0	0	0	0
Interest paid	(25,139)	(23,962)	(28,584)	(33,699)	(31,741)	(29,784)	(27,826)	(25,869)	(23,911)
Others	(1,093)	(648)	(64,994)	(39,684)	0	0	0	0	0
Net cash from financing activities	28,061	(39,128)	(184,037)	(89,228)	(196,390)	(220,264)	(244,452)	(259,686)	(274,221)
Net change in cash	10,967	23,163	19,603	263,985	264,789	171,964	350,400	309,991	406,907
Cash at beginning of period	337,004	368,660	380,393	393,905	697,827	962,616	1,134,580	1,484,979	1,794,970
Exchange (losses)/gains	20,689	(11,430)	(6,091)	7,373	0	0	0	0	0
Cash restatement	0	0	0	32,564	0	0	0	0	0
Cash at end of period	368.660	380.393	393.905	697.827	962.616	1.134.580	1,484,979	1,794,970	2,201,877



Exhibit 9 - Key ratios

Ratios									
	2017	2018	2019	2020	2021E	2022E	2023E	2024E	2025E
AR days	65	63	61	75	65	60	60	60	60
AP days	21	18	20	23	20	20	20	20	20
Inventory days	25	28	33	40	35	35	35	35	35
Capex as % of sales	8.8%	6.1%	5.8%	3.3%	4.0%	4.0%	2.0%	2.0%	2.0%
D&A as % of PP&E	30.7%	17.6%	13.3%	11.8%	12.0%	12.0%	12.0%	12.0%	12.0%
Current ratio	1.7x	3.1x	2.1x	2.3x	2.7x	3.0x	3.6x	4.2x	4.8x
Quick ratio	1.6x	2.8x	1.9x	2.1x	2.5x	2.8x	3.4x	3.9x	4.6x
Cash ratio	0.7x	1.2x	0.8x	1.2x	1.6x	1.9x	2.4x	2.9x	3.6x
OCF/share	0.2	0.2	0.3	0.4	0.6	0.5	0.7	0.7	0.8
FCF/share	0.0	0.1	0.2	0.3	0.5	0.4	0.6	0.6	0.7
ROA	5%	3%	5%	3%	9%	10%	11%	11%	12%
ROE	7%	4%	8%	5%	13%	15%	16%	16%	15%
Dividend pay-out ratio	30%	39%	32%	63%	35%	35%	35%	35%	35%
Net Gearing Ratio	17%	22%	20%	7%	-6%	-14%	-25%	-34%	-42%



Company Description

Modern Dental

Modern Dental is a global dental prosthetic device provider with two major product lines: fixed prosthetic devices such as crowns and bridges; and removable prosthetic devices such as removable dentures.

Company Valuation/Risks

Modern Dental

Our PEG based PT for Modern Dental is HK\$7.3. Risks: goodwill impairment, ASP pressure, competition, M&A integration risks.

Analyst Certification:

I, Christopher Lui, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

I, Ruyi Tang, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

I, Gabriel Wong, PhD, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

Registration of non-US analysts: Christopher Lui is employed by Jefferies Hong Kong Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: Ruyi Tang, CFA is employed by Jefferies Hong Kong Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: Gabriel Wong, PhD is employed by Jefferies Hong Kong Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

As is the case with all Jefferies employees, the analyst(s) responsible for the coverage of the financial instruments discussed in this report receives compensation based in part on the overall performance of the firm, including investment banking income. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Aside from certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgement.

Investment Recommendation Record

(Article 3(1)e and Article 7 of MAR)	
Recommendation Published	April 25, 2021 , 22:33 ET.
Recommendation Distributed	April 25, 2021 , 22:33 ET.

Explanation of Jefferies Ratings

Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period.

Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 10% within a 12-month period.

Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus 10% or less within a 12-month period.

The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \$10 is 20% or more within a 12-month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \$10, the expected total return (price appreciation plus yield) is



plus or minus 20% within a 12-month period. For Underperform rated securities with an average security price consistently below \$10, the expected total return (price appreciation plus yield) is minus 20% or less within a 12-month period.

NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.

CS - Coverage Suspended. Jefferies has suspended coverage of this company.

NC - Not covered. Jefferies does not cover this company.

Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.

Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.

Valuation Methodology


Jefferies' methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/ average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

Jefferies Franchise Picks

Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.

Risks which may impede the achievement of our Price Target

This report was prepared for general circulation and does not provide investment recommendations specific to individual investors. As such, the financial instruments discussed in this report may not be suitable for all investors and investors must make their own investment decisions based upon their specific investment objectives and financial situation utilizing their own financial advisors as they deem necessary. Past performance of the financial instruments recommended in this report should not be taken as an indication or guarantee of future results. The price, value of, and income from, any of the financial instruments mentioned in this report can rise as well as fall and may be affected by changes in economic, financial and political factors. If a financial instrument is denominated in a currency other than the investor's home currency, a change in exchange rates may adversely affect the price of, value of, or income derived from the financial instrument described in this report. In addition, investors in securities such as ADRs, whose values are affected by the currency of the underlying security, effectively assume currency risk.





Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company. <u>Legend:</u>

I: Initiating Coverage

D: Dropped Coverage

B: Buy

H: Hold

UP: Underperform

Distribution of Ratings

Distribution of Ratings									
			IB Serv./Pa	ast12 Mos.	JIL Mkt Serv./Past12 Mos.				
	Count	Percent	Count	Percent	Count	Percent			
BUY	1691	61.67%	179	10.59%	25	1.48%			
HOLD	919	33.52%	22	2.39%	6	0.65%			
UNDERPERFORM	132	4.81%	2	1.52%	1	0.76%			

Other Important Disclosures

Jefferies does business and seeks to do business with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Group LLC ("Jefferies") group companies:

United States: Jefferies LLC which is an SEC registered broker-dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).

United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority; registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.

Hong Kong: Jefferies Hong Kong Limited, which is licensed by the Securities and Futures Commission of Hong Kong with CE number ATS546; located at Suite 2201, 22nd Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

Singapore: Jefferies Singapore Limited, which is licensed by the Monetary Authority of Singapore; located at 80 Raffles Place #15-20, UOB Plaza 2, Singapore 048624, telephone: +65 6551 3950.

Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006; telephone +813 5251 6100; facsimile +813 5251 6101.

India: Jefferies India Private Limited (CIN - U74140MH2007PTC200509), licensed by the Securities and Exchange Board of India for: Stock Broker (NSE & BSE) INZ000243033, Research Analyst INH000000701 and Merchant Banker INM000011443, located at 42/43, 2 North Avenue, Maker Maxity, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051, India; Tel +91 22 4356 6000.

Australia: Jefferies (Australia) Securities Pty Limited (ACN 610 977 074), which holds an Australian financial services license (AFSL 487263) and is located at Level 22, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.

This report was prepared by personnel who are associated with Jefferies (Jefferies International Limited, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC ("JRS"). Jefferies LLC is a US registered broker-dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as "Jefferies". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA and other rules are set forth in this disclosure section.

If you are receiving this report from a non-US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited ("JIL") and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed.

JIL allows its analysts to undertake private consultancy work. JIL's conflicts management policy sets out the arrangements JIL employs to manage any potential conflicts of interest that may arise as a result of such consultancy work. Jefferies LLC, JIL and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under "company specific disclosures".

For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a "Designated Institution" as defined by the Securities Act (Ontario). In Singapore, Jefferies Singapore Limited ("JSL") is regulated by the Monetary Authority of Singapore. For investors in the Republic of Singapore, this material is provided by JSL pursuant to Regulation 32C of the Financial Advisers Regulations. The material contained in this document is intended solely for accredited, expert or institutional investors, as defined under the Securities and Futures Act (Cap. 289 of Singapore). If there are any matters arising from, or in

connection with this material, please contact JSL, located at 80 Raffles Place #15-20, UOB Plaza 2, Singapore 048624, telephone: +65 6551 3950. In Japan, this material is issued and distributed by Jefferies (Japan) Limited to institutional investors only. In Hong Kong, this report is issued and approved by Jefferies Hong Kong Limited and is intended for use only by professional investors as defined in the Hong Kong Securities and Futures Ordinance and its subsidiary legislation. In the Republic of China (Taiwan), this report should not be distributed. The research in relation to this report is conducted outside the People's Republic of China ("PRC"). This report does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. In India, this report is made available by Jefferies India Private Limited. In Australia, this report is issued and/or approved for distribution by, or on behalf of, Jefferies (Australia) Securities Pty Ltd. It is directed solely at wholesale clients within the meaning of the Corporations Act 2001 of Australia (the "Corporations Act"), in connection with their consideration of any investment or investment service that is the subject of this report. This report may contain general financial product advice. Where this report refers to a particular financial product, you should obtain a copy of the relevant product disclosure statement or offer document before making any decision in relation to the product. Recipients of this document in any other jurisdictions should inform themselves about and observe any applicable legal requirements in relation to the receipt of this document.

This report is not an offer or solicitation of an offer to buy or sell any security or derivative instrument, or to make any investment. Any opinion or estimate constitutes the preparer's best judgment as of the date of preparation, and is subject to change without notice. Jefferies assumes no obligation to maintain or update this report based on subsequent information and events. Jefferies, and their respective officers, directors, and employees, may have long or short positions in, or may buy or sell any of the securities, derivative instruments or other investments mentioned or described herein, either as agent or as principal for their own account. This material is provided solely for informational purposes and is not tailored to any recipient, and is not based on, and does not take into account, the particular investment objectives, portfolio holdings, strategy, financial situation, or needs of any recipient. As such, any advice or recommendation in this report may not be suitable for a particular recipient. Jefferies assumes recipients of this report are capable of evaluating the information contained herein and of exercising independent judgment. A recipient of this report should not make any investment decision without first considering whether any advice or recommendation in this report is suitable for the recipient based on the recipient's particular circumstances and, if appropriate or otherwise needed, seeking professional advice, including tax advice. Jefferies does not perform any suitability or other analysis to check whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs. By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker-dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.

The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.

This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.

This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third-party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses,



legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Jefferies. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.

For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/ crd_iapd_Brochure.aspx?BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https:// javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES. © 2021 Jefferies Group LLC